News FDA fast-tracks Sanofi's gene therapy for eye disease GA Sanofi has been granted a speedy review from the FDA for a gene therapy for geographic atrophy, a major cause of blindness.
News After FDA says no, Bayer bags EU nod for twice-yearly Eylea Bayer has been given a leg up in the competitive market for VEGF therapies used to treat eye diseases with a new EU approval for Eylea 8mg.
News Boehringer advances oral therapy for geographic atrophy Boehringer Ingelheim has started a phase 2 trial of a drug that could offer the first oral drug for geographic atrophy, a major cause of sight loss.
News Phase 3 readout puts Opthea at risk of insolvency After its lead wet AMD drug failed a phase 3 trial, Opthea may have to make massive repayments to investors that would threaten its viability.
News FDA changes its mind on Astellas' geographic atrophy drug Astellas has shored up the competitive profile of Izervay for eye disorder geographic atrophy, getting FDA approval for extended treatment.
News FDA says no to Astellas' geographic atrophy drug Astellas has suffered another major setback with geographic atrophy (GA) treatment Izervay, this time in the US.
News NHS staff 'feel unprepared for digital transformation' A survey of NHS workers has found that almost two-thirds feel they are unprepared for the digital transformation objectives of the 10-Year Plan.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
